Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study

Clinical Genitourinary Cancer

Volumn 7, Issue 3, 2009, Pages

  Thompson, John A ^a   Kuzel, Timothy ^b   Drucker, Beverly J ^c   Urba, Walter ^d   Bukowski, Ronald ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Immunotherapy; Inducible protein 10; Maximum tolerated dose; Toll like receptor 9

Indexed keywords

AGATOLIMOD; ALPHA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12P40; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPOPHOSPHATEMIA; HYPOTENSION; INJECTION SITE REACTION; KIDNEY CARCINOMA; LEUKOPENIA; LUNG METASTASIS; LYMPHOCYTOPENIA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEMORY DISORDER; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RIGOR; RISK ASSESSMENT; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUMOR VOLUME; WEAKNESS;

EID: 70449127697     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.025     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008.
2. CA Cancer J Clin 2008; 58:71-96.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335:865-875
4. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006; 24:5601-5608
5. Bukowski RM, Novick AC. Clinical practice guidelines: renal cell carcinoma. Cleve Clin J Med 1997; 64(suppl 1):SI1-44.
6. Tomita Y. Early renal cell cancer. Int J Clin Oncol 2006; 11:22-27
7. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004; 10:6342s-6s.
8. Fisher RI, Rosenberg SA, Sznol M, et al. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997; 3(suppl 1):S70-2.
9. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-296
10. Kidney cancer. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-v.2.2007. National Comprehensive Cancer Network [Web site]. Available at: http://www.nccn.org/professionals/physician-gls/PDF/kidney. pdf. Accessed July 12, 2007.
11. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134
12. Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, doubleblind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 2007; 25(suppl):2s (Abstract 3).
13. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281 (Pubitemid 46849157)
14. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-484
15. Noll BO, McCluskie MJ, Sniatala T, et al. Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. Biochem Pharmacol 2005; 69:981-991
16. Link BK, Ballas ZK, Weisdorf D, et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 2006; 29:558-568
17. American Cancer Society. Cancer Facts and Figures 2006. Atlanta, GA: American Cancer Society; 2006.
18. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma- specific death. J Clin Oncol 2002; 20:791-796
19. Pashenkov M, Goess G, Wagner C, et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006; 24:5716-5724
20. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of highdose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-141
21. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124 (Pubitemid 46089672)
22. Jonasch E, Corn P, Ashe RG, et al. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 2007; 25(suppl):260s (Abstract 5104).